Loracarbef

Structural formula
General
Non-proprietary name	Loracarbef
other names	(6 R , 7 S ) -7 - (( R ) -2-Amino-2-phenylacetamido) -3-chloro-8-oxo-1-azabicyclo [4.2.0] oct-2-en-2-carboxylic acid
Molecular formula	C 16 H 16 ClN 3 O 4
External identifiers / databases
PubChem	5284585
ChemSpider	4447635
DrugBank	DB00447
Wikidata	Q979521
Drug information
ATC code	J01 DC08
Drug class	β-lactam antibiotics
Mechanism of action	Inhibition of bacterial cell wall synthesis
properties
Molar mass	349.76 g · mol -1
Physical state	firmly
Melting point	205–215 ° C (decomposition)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Loracarbef (trade name Lorafem ^® ) is a drug from the group of β-lactam antibiotics that is used to treat infections of the ear, nose and throat. It belongs to the oral carbacephemes , a subgenus of the cephalosporins and is assigned to the second generation. It has a similar spectrum of activity to Cefaclor and differs structurally from it in that the sulfur atom is replaced by a methylene group . It was patented by Kyōwa Hakkō Kirin in 1980 . Loracarbef has been in the USA since 2006 and no longer in Germany in 2009.

Clinic & Pharmacology

The antibacterial activity of Loracarbef extends to Streptococcus pyogenes , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , Staphylococcus aureus , Staphylococcus epidermidis , Escherichia coli , Proteus mirabilis and Klebsiella pneumoniae . The bactericidal effect is based on the inhibition of an enzyme that is required for the construction of the peptidoglycan cell wall.

Symptoms in the gastrointestinal system (nausea, diarrhea, vomiting), dizziness and headaches are known to be possible side effects.

The bioavailability is over 90 percent. Excretion takes place renally .

Individual evidence

↑ ^a ^b ^c Entry on Loracarbef. In: Römpp Online . Georg Thieme Verlag, accessed on June 23, 2014.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Loracarbef - the first carbacephem for oral use . In: Zeitschrift zur Chemotherapie , Issue 6, 1993, accessed on July 21, 2019.
↑ H. Lüllmann, K. Mohr, L. Hein: Pharmakologie und Toxikologie , 17th edition, Georg Thieme Verlag, Stuttgart 2010, ISBN 978-3-13-151647-3 , p. 486.
↑ Hans-Reinhard Brodt: Antibiotic Therapy , 12th edition, p. 88.
↑ Sitar DS, Hoban DJ, Aoki FY (1994): Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state. In: J Clin Pharmacol . 34: 924-929. PMID 7983236 .

[RömppOnline-1] Entry on Loracarbef. In: Römpp Online . Georg Thieme Verlag, accessed on June 23, 2014.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] Loracarbef - the first carbacephem for oral use . In: Zeitschrift zur Chemotherapie , Issue 6, 1993, accessed on July 21, 2019.

[Lüllmann-4] H. Lüllmann, K. Mohr, L. Hein: Pharmakologie und Toxikologie , 17th edition, Georg Thieme Verlag, Stuttgart 2010, ISBN 978-3-13-151647-3 , p. 486.

[5] Hans-Reinhard Brodt: Antibiotic Therapy , 12th edition, p. 88.

[6] Sitar DS, Hoban DJ, Aoki FY (1994): Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state. In: J Clin Pharmacol . 34: 924-929. PMID 7983236 .